Immunoglobulin G4-related disease: Multiple organ occupation on CT.

One case involved a 61-year-old woman who was admitted to hospital with liver occupation, subsequently found multiple organ occupation, and was eventually pathologically identified as having immunoglobulin G4-related disease.

A case of hemophagocytic syndrome secondary to B-cell lymphoma.

In this report we highlight a case of HPS secondary to B-cell lymphoma, aiming to facilitate the early recognition and treatment of HPS in its classic presentation by clinicians.

The alleviating effect and mechanism of GLP-1 on ulcerative colitis.

Ulcerative Colitis (UC) is a major type of chronic inflammatory bowel disease of the colonic mucosa and exhibits progressive morbidity. The incidence and prevalence of UC is increasing worldwide. The global burden of UC, which can substantially reduce quality of life, is clearly increasing.

Interleukin-35 dampens T helper 22 phenotype shift in CD4CD25CD127 regulatory T cells in primary biliary cholangitis.

The phenotype shift in regulatory T cells (Tregs) contributes to immunopathogenesis of autoimmune diseases. The current study was aimed to investigate the regulatory function of interleukin-35 (IL-35) to T helper 22 (Th22) cell phenotype shift in Tregs in primary biliary cholangitis (PBC). Fifty-five PBC patients and twenty-four controls were enrolled.

Research progress on short-term prognosis of acute-on-chronic liver failure.

Introduction: Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized as a severe condition with rapid progression, poor therapeutic response and poor prognosis. Early and timely evaluation of the prognosis is helpful for providing appropriate clinical intervention and prolonging patient survival.

Areas Covered: Currently, there are no specific dynamic and comprehensive approaches to assess the prognosis of patients with ACLF.

Overexpression of ascitic interleukin-35 induces CD8 T cell exhaustion in liver cirrhotic patients with spontaneous bacterial peritonitis.

Interleukin (IL) -35 induces immunotolerance by suppression of CD8 T cells during chronic infections and cancers. In the present study, we amined to investigate the role of IL-35-mediated regulation of CD8 T cells in patients with liver cirrhosis. Seventy-one patients with liver cirrhosis (46 patients with untainted ascites and 25 patients with spontaneous bacterial peritonitis [SBP]) and 22 controls were enrolled.

Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.

Natural killer-like B (NKB) cells are newly identified lymphocyte subset, which present immunomodulatory property in infectious diseases through secretion of interleukin-18 (IL-18). However, the role of NKB cells function and its regulation in hepatocellular carcinoma (HCC) is not elucidated. Seventy-two HCC patients and twenty-five controls were enrolled.

Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.

Background: Pradefovir is a liver-targeted prodrug of adefovir, a nucleoside/nucleotide analogue with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30, 45, 60, or 75 mg) versus tenofovir disoproxil fumarate (TDF; 300 mg) and aimed to identify the most appropriate dose of pradefovir for the forthcoming phase 3 study.

Methods: Treatment-naive and experienced (not on treatment >6 months) patients with chronic hepatitis B were eligible.

Interleukin-35 Suppresses Interleukin-9-Secreting CD4 T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma.

Chronic hepatitis B virus (HBV) infection induces dysfunction of immune response and chronic liver damage. However, the mechanisms that account for HBV-related hepatocellular carcinoma (HCC) are poorly understood. The aim of present study was to investigate the modulatory role of interleukin (IL)-35, an immunosuppressive cytokine, to IL-9-secreting T cells in hepatitis B-related HCC.

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks.

Background: In some previous studies, serum hepatitis B virus RNA (HBV RNA) was proposed as an HBV viral marker during therapy. However, the dynamic change of HBV RNA, the correlation of HBV RNA with cccDNA, and the combination of HBV RNA with known HBV markers in predicting entecavir (ETV) treatment outcome in the same cohort are rarely reported.

Methods: A total of 111 HBeAg-positive patients were enrolled in our study.

Interleukin-35 Suppresses CD8 T Cell Activity in Patients with Viral Hepatitis-Induced Acute-on-Chronic Liver Failure.

Background: Interleukin (IL)-35 is a newly indentified cytokine and induces immunotolerance via suppression of CD8 T cell activity in chronic viral hepatitis.

Aims: To investigate the modulatory function of IL-35 to CD8 T cells in viral hepatitis-induced acute-on-chronic liver failure (ACLF).

Methods: Fifty-five ACLF patients and 21 healthy controls were enrolled.

Interleukin-35 Dampens CD8 T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma.

Interleukin (IL)-35 is a newly identified IL-12 cytokine family member, which has been demonstrated to induce immunotolerance by suppression of CD8 T cells function in chronic viral hepatitis. However, the role of IL-35 in modulating CD8 T cells activity in non-viral hepatitis-related hepatocellular carcinoma (HCC) was not fully elucidated. Forty-four patients with non-viral hepatitis-related HCC and 20 healthy individuals were enrolled.

Interleukin-35 modulates the balance between viral specific CD4CD25CD127 regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection.

Background: Interleukin (IL)-35 regulates imbalance between regulatory T cells (Tregs) and T helper (Th) 17 cells, leading to an important modulator in autoimmune disorder, cancer, and infectious diseases. Our previous study revealed an immunosuppressive activity of IL-35 in chronic hepatitis B virus (HBV) infection. Thus, the aim of the current study was to investigate the role of regulatory function of IL-35 to viral specific Tregs/Th17 cells balance in chronic HBV infection.

Decoy receptor 3 alleviates hepatic fibrosis through suppressing inflammation activated by NF-κB signaling pathway.

Background: Hepatic fibrosis is a reversible pathological process. Inflammatory responses are the prevailing reactions during hepatic fibrosis. Decoy receptor 3 (DcR3) has been reported to have an anti-inflammatory effect.

Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.

The mechanisms of hepatitis B virus (HBV) persistent infection are not completely understood. Interleukin (IL)-35, which is a newly identified cytokine belongs to IL-12 family, has been demonstrated to induce immunotolerance. Thus, the aim of current study was to investigate the role of IL-35 during chronic HBV infection.

An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection.

Interleukin (IL)-35, a newly identified member of the IL-12 cytokine family, has been reported to suppress inflammation and induce immunotolerance. However, little is known regarding the role of IL-35 during chronic hepatitis C virus (HCV) infection. Herein, we measured the serum IL-35 concentration of 73 patients with hepatitis C and 22 healthy individuals, as well as further investigated the modulatory function of IL-35 on CD4CD25CD127 regulatory T cells (Tregs) and on hepatocytes infected with HCV in cell culture (HCVcc).

Efficacy and Safety of High Specific Volume Polysaccharide-A New Type of Dietary Fiber for Treatment of Functional Constipation and IBS-C.

We investigated the efficacy and safety of a new type of dietary fiber (high specific volume polysaccharide) for use in treating constipation of different etiologies. Functional constipation patients and irritable bowel syndrome-constipation (IBS-C) patients were administrated high specific volume polysaccharide (HSVP) three times daily for a period of 2 wk to relieve their symptoms. Scores on a stool form scale, and patient reports of straining during a bowel movement, having sensations of an incomplete bowel movement or a blocked anorectum, and abnormal defecation intervals were recorded, graded, and scored by a functional constipation sample group.

[Gene therapy based on inducible IL-12 gene in a mouse model of orthotopically transplanted H22 hepatoma].

Objective: To evaluate the antitumor efficiency of IL-12 gene induced by RU486 regulatory system in a mouse model of orthotopically transplanted hepatoma.

Methods: The orthotopic hepatoma model was prepared by inoculation of H22 hepatoma cells into the mouse liver. Murine interleukin-12 (IL-12) expressing plasmid pRS22 containing RU486 regulatory system was injected into mice by a hydrodynamic injection 3 days after H22 cells inoculation.

[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis].

Objective: To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis.

Methods: Six hepatic cirrhosis (Child-Pugh A grade, liver function compensated) patients complicated with hepatitis B virus associated glomerulonephritis diagnosed by renal biopsy, real time PCR and urinary protein tests were treated with ADV for one year in addition to a routine treatment. The dosage of ADV was 100mg daily.